Drug intelligence / Profile preview

G-238

Development stage: Unknown
Lead developer: Laboratorios Salvat
Modality: Small Molecules
Administration: Otic

Overview

G-238 is a small molecule drug initially developed by Editorial Salvat. It has been investigated primarily for the treatment of otomycosis, a fungal infection of the ear canal. The drug has reached Phase 3 clinical trials, where it was compared to clotrimazole 1% otic solution in patients with otomycosis. Its mechanism of action and molecular target have not been publicly disclosed. The highest reported development status is "Pending" as of March 2025, and there are no indications that it has received regulatory approval or commercial launch[4].

Other names: G238G-238G 238

Beyond the preview

Go deeper on G-238.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G-238.

Explore the full profile